Curasight announces that all nine clinical centers in Germany, Sweden and Denmark are now recruiting patients for part 2 of the phase II study of uTRACE in prostate cancer. Part 1 of the study was completed earlier in 2025. Recruitment for part 2 is expected to be completed in the first half of 2026. The study is being conducted under the collaboration agreement with Curium Inc. from May 2023, where Curasight may receive up to USD 70 million in milestone payments.
|
Published October 29, 2025
Curasight advances with phase II study in prostate cancer
Text:
News Desk [email protected]
Notes
Diamyd Medical reaches milestone in phase III study – screening completed
BrainCool receives grant funding from the EU of SEK 6 million
Qlife collaborates on AI-powered diabetes management in China
Eli Lilly reports 29 percent weight loss
Zealand Pharma enters into billion-dollar deal with OTR Therapeutics
Nanexa and Moderna enter into agreement potentially worth over USD 500 million
Flerie's portfolio company AnaCardio reports strong Phase IIa results
NEWSLETTER
Today's news roundup
The news sweep Friday 12 December
Upcoming events
MedTech Summit 2026
A new, much-needed MedTech forum in one of Europe's leading life science clusters. As the first event of its kind...
Global Forum 2026
This May, our premier event returns, dramatically expanded yet carefully curated to ensure a welcoming and high-value experience. We ha...
Investing in Life Science
Set in vibrant Stockholm, the Swedish finance capital, this boutique investor event connects regional life science leaders looking for strategic...
Recommended
Giant investment in Danish biotech
CuraCell demonstrates durable immune control in prostate cancer
BiBBInstruments validates clinical need during US tour
Sunstone sounds the alarm: “Danish startups are running on fumes”
Sprint Bioscience: "We have shown it is possible to make early deals"
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account